missing translation for 'onlineSavingsMsg'
Learn More

Gibco™ Human IL-28A (IFN-lambda 2) Recombinant Protein, PeproTech®

Artikelnummer. 17810523
Click to view available options
Menge:
1 mg
100 μg
20 μg
250 μg
5 μg
500 μg
Packungsgröße:
1 Milligramm
100 Mikrogramm
20 Mikrogramm
250 Mikrogramm
5 Mikrogramm
500 Mikrogramm
Dieser Artikel kann nicht zurückgegeben werden. Rückgaberichtlinie anzeigen

Artikelnummer. 17810523

Marke: Gibco™ 30002K5UG

om dit product te kopen Registreer vandaag om een webaccount aan te maken

Dieser Artikel kann nicht zurückgegeben werden. Rückgaberichtlinie anzeigen

Recombinant Protein

Recombinant Human IFN-lambda2 is a 19.6 kDa protein containing 174 amino acid residues. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

IL-28A belongs to the IFN lambda family, a novel family of cytokines within the IL-10 superfamily. The three members of this family are IL-29 (IFN lambda 1), IL-28A (IFN lambda 2), and IL-28B (IFN lambda 3), and are also known as the type III Interferons.The IFN lambdas signal through a heterodimeric receptor of which one subunit, IL-10R2, is shared with other members of the superfamily. The second subunit, IFN lambda R1 or IL-28R alpha, is unique to the IFN lambdas. Signaling occurs through the Jak/STAT pathway in a similar manner as the type I IFN (IFN alpha/beta) and activates many of the same genes despite low sequence homology between the cytokines and receptors in the two families. Both IFN families display antiviral activity through the induction of antiviral protein production in target cells and the upregulation of MHC class I expression. These proteins also exhibit antiproliferative and antitumor effects, making them a possible alternative to IFN alpha cancer therapies. Unlike the type I IFN, which are able to stimulate most cells, response to IFN lambda stimulation appears to be limited to dendritic and some tumor cells due to the limited expression of IFN lambda R1. Another notable difference is the ability of the IFN lambda stimulation to drive dendritic cells towards the production of CD4+CD25+FoxP3+ regulatory T cells, suggesting a possible immunoregulatory role
TRUSTED_SUSTAINABILITY

Specifications

Zugriffsnummer Q8IZJ0
Zur Verwendung mit (Anwendung) ELISA, Functional Assay, Western Blot
Zusammensetzung protein with no preservative
Gen-ID (Entrez) 282616
Molekulargewicht 19.6 kDa
Name Human IL-28 A (IFN-lambda 2)
Menge 5 μg
Quelle E. coli
Kennzeichnung RUO
Endotoxin-Konzentration <1 EU/ μg
Gen-Alias cytokine Zcyto20; EG330496; Ifnl2; IFN-lambda2; IFN-lambda-2; Il28a; IL-28 A; ILN; interferon lambda 2; interferon lambda-2; interferon, lambda 2; interferon-lambda 2; interferon-lambda2; Interleukin; interleukin 28 A; interleukin 28 A (interferon, lambda 2); interleukin-28 A; ZCYTO20
Gebräuchliche Bezeichnung IL-28 A
Gensymbol IFNL2
Biologische Aktivität Determined by its ability to activate STAT phosphorylation in an ISRE Luciferase Reporter Assay using human colon carcinoma COLO205 cells. The expected ED50 is 0.3-0.5 ng/ml
Konjugat Unconjugated
Rekombinant Recombinant
Sequenz PVARLHGALP DARGCHIAQF KSLSPQELQA FKRAKDALEE SLLLKDCRCH SRLFPRTWDL RQLQVRERPM ALEAELALTL KVLEATADTD PALVDVLDQP LHTLHHILSQ FRACIQPQPT AGPRTRGRLH HWLYRLQEAP KKESPGCLEA SVTFNLFRLL TRDLNCVASG DLCV
Inhalt und Lagerung -20°C
Expressionssystem E. coli
Form Lyophilized
Reinheits- oder Qualitätsgrad ≥ 98% by SDS-PAGE gel and HPLC analyses.
Show More Show Less
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.